Avelumab and Merkel Cell Carcinoma: Evaluating the Evidence
From General Health Information to Specific Drug Safety
The legacy of general health and science information dissemination has long served as a foundation for public understanding, offering broad guidance on wellness, disease prevention, and the safe use of medical interventions. Within this heritage, the communication of pharmaceutical benefits and risks has been a central pillar, ensuring that patients and providers alike can make informed decisions based on available data. This context naturally extends to the evaluation of therapeutic agents used in oncology, where the balance between efficacy and adverse effects is critically examined. As the focus narrows from general health principles to specific clinical applications, the discussion must pivot toward the nuanced relationship between drug exposure and subsequent health outcomes. In the domain of mass production, where pharmaceuticals are manufactured and distributed at scale, the imperative to monitor for rare or delayed adverse events becomes paramount. This transition leads directly to the occupational exposure concern: the potential for unintended consequences when a therapeutic agent, such as Avelumab, is associated with the development of a malignancy like Merkel Cell Carcinoma. The shift from a general health context to a specific exposure-risk paradigm requires careful consideration of how such associations are investigated and communicated within the framework of public health and industrial safety.
Avelumab: Mechanism and Clinical Use in Merkel Cell Carcinoma
Avelumab is a fully human IgG1 monoclonal antibody that functions as an immune checkpoint inhibitor by targeting programmed cell death ligand 1 (PD-L1) (https://pubmed.ncbi.nlm.nih.gov/29799096/). It has been approved in the USA, the EU, and Japan for the treatment of metastatic Merkel cell carcinoma (MCC), a rare and aggressive neuroendocrine cutaneous malignancy with poor prognosis (https://pubmed.ncbi.nlm.nih.gov/33439294/;https://pubmed.ncbi.nlm.nih.gov/29799096/). The approval was based on the JAVELIN Merkel 200 phase II trial, in which confirmed objective responses were observed in approximately one-third of patients with chemotherapy-refractory metastatic MCC treated with avelumab (https://pubmed.ncbi.nlm.nih.gov/29799096/). However, despite these advances, about 50% of patients with advanced MCC treated with immune checkpoint inhibitors progress on therapy (https://pubmed.ncbi.nlm.nih.gov/35877101/). Merkel cell carcinoma is associated with chronic exposure to ultraviolet light and the Merkel cell polyoma virus, and its incidence is increasing (https://pubmed.ncbi.nlm.nih.gov/35877101/). The disease is characterized by high rates of recurrence and mortality (https://pubmed.ncbi.nlm.nih.gov/35877101/). Clinical presentation typically involves a rapidly growing, painless, firm, red or purple nodule on sun-exposed skin, often in older or immunocompromised individuals. Diagnosis is confirmed by histopathology and immunohistochemistry, showing neuroendocrine differentiation (https://pubmed.ncbi.nlm.nih.gov/33439294/). For patients with metastatic MCC, systemic therapy options include avelumab as a first-line or later-line treatment, independent of line of therapy (https://pubmed.ncbi.nlm.nih.gov/29799096/).
Adverse Effects and Immune-Related Events
The pharmacology of avelumab involves blocking PD-L1, thereby preventing the inhibition of T-cell activity and enhancing the immune response against tumor cells. However, this mechanism can also lead to overactivation of the immune system, resulting in immune-related adverse events (irAEs) (https://pubmed.ncbi.nlm.nih.gov/31543781/). Reported adverse effects include hypercalcaemia due to reactivation of sarcoidosis, as described in a case report where a patient with metastatic MCC on avelumab developed hypercalcaemia secondary to sarcoidosis, which was managed with corticosteroids and allowed continuation of avelumab therapy (https://pubmed.ncbi.nlm.nih.gov/31543781/). Other irAEs are common with checkpoint inhibitors, but specific data on avelumab-associated MCC risk are limited. Mechanistic pathways linking avelumab to MCC are not directly causative; rather, avelumab is used to treat MCC. The drug does not cause MCC but is indicated for its treatment. However, in the context of avelumab-refractory MCC, where patients progress on therapy, subsequent treatment options include combined ipilimumab and nivolumab, which have shown responses in some patients (https://pubmed.ncbi.nlm.nih.gov/33439294/;https://pubmed.ncbi.nlm.nih.gov/36450381/;https://pubmed.ncbi.nlm.nih.gov/35877101/). This suggests that resistance to avelumab may involve mechanisms such as upregulation of alternative immune checkpoints or tumor heterogeneity, but these are not direct causal links from avelumab to MCC development.
Risk Context and Causation Considerations
Regarding risk anchors, the adequacy of warnings about avelumab and MCC is reflected in the drug's approval for metastatic MCC, which inherently acknowledges the disease as a target rather than a risk. The prescribing information for avelumab includes warnings about immune-related adverse events, but not about causing MCC, as the drug is therapeutic. Causation-related considerations for affected patients focus on whether avelumab treatment could worsen or alter the course of MCC. Evidence indicates that avelumab can induce responses in some patients, but about half progress, and for those refractory, alternative immunotherapies may be effective (https://pubmed.ncbi.nlm.nih.gov/35877101/). The timeline between exposure and documented harm is typically measured in weeks to months, as irAEs can occur during treatment, but progression of MCC itself may occur despite therapy. For example, in the JAVELIN Merkel 200 trial, responses were assessed over time, and progression was documented in non-responders (https://pubmed.ncbi.nlm.nih.gov/29799096/). In avelumab-refractory patients, subsequent treatment with ipilimumab plus nivolumab showed responses in three out of five patients in one study, indicating that harm from avelumab is primarily lack of efficacy rather than direct causation of MCC (https://pubmed.ncbi.nlm.nih.gov/33439294/). In summary, avelumab is an effective treatment for metastatic MCC, but it is associated with immune-related adverse events and a significant proportion of patients do not respond or progress. The drug does not cause MCC; rather, it is used to manage the disease. Warnings appropriately focus on irAEs, and causation considerations for affected patients should address treatment failure and alternative options.
Important Notice
This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.
Frequently Asked Questions
Does avelumab cause Merkel cell carcinoma?
No, avelumab is used to treat Merkel cell carcinoma (MCC). It is an immune checkpoint inhibitor that targets PD-L1 and has been approved for metastatic MCC. The drug does not cause MCC; rather, it is indicated for its treatment. However, about half of patients may not respond or may progress on therapy, which is a concern for treatment efficacy rather than causation.
What are the main risks associated with avelumab?
The main risks are immune-related adverse events (irAEs) due to overactivation of the immune system. These can include conditions like hypercalcaemia from sarcoidosis reactivation, as reported in a case study (https://pubmed.ncbi.nlm.nih.gov/31543781/). Other common irAEs include skin reactions, colitis, hepatitis, and pneumonitis. The prescribing information includes warnings about these events, but not about causing MCC.
What should I do if I have been treated with avelumab and developed Merkel cell carcinoma?
If you have been treated with avelumab and developed MCC, it is important to understand that avelumab is used to treat MCC, not cause it. However, if you have concerns about your treatment or progression, consult your healthcare provider. For those with documented avelumab exposure and a confirmed MCC diagnosis, an independent eligibility review may be available through the Information Registry.
Does submitting information create an attorney-client relationship?
No. Submission requests an initial records screening only and does not create an attorney-client relationship.
This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.